Enterprise Value

1.162B

Cash

527.1M

Avg Qtr Burn

-34.45M

Short % of Float

20.25%

Insider Ownership

1.07%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tipifarnib Details
Cancer, Head and neck cancer, Head and neck squamous cell carcinoma

Phase 2

Data readout

Ziftomenib (menin inhibitor) (KO-539) Details
Acute myeloid leukemia, Blood cancer, Cancer

Phase 2

Data readout

Tipifarnib Details
Cancer, Lymphoma, T-cell lymphoma

Phase 2

Update

Tipifarnib + alpelisib Details
Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Phase 1/2

Update

Phase 1

Data readout

KO-2806 (FTI inhibitor) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Data readout

Ziftomenib + gilteritinib Details
Acute myeloid leukemia, Blood cancer, Cancer

Phase 1

Data readout

KO-2806 (FTI inhibitor) + cabozantinib Details
Solid tumor/s, Renal cell carcinoma, Cancer

Phase 1

Data readout